's Bulletin Board Post A Reply
my profile login | register | search | faq | forum home

»'s Bulletin Board » .11 and Up! » SBFM SUNSHINE BIOPHARMA INC » Post A Reply

Post A Reply
Login Name:
Message Icon: Icon 1     Icon 2     Icon 3     Icon 4     Icon 5     Icon 6     Icon 7    
Icon 8     Icon 9     Icon 10     Icon 11     Icon 12     Icon 13     Icon 14    

HTML is enabled.
UBB Code™ is enabled.


Instant Graemlins Instant UBB Code™
Smile   Frown   Embarrassed   Big Grin   Wink   Razz  
Cool   Roll Eyes   Mad   Eek!   Confused   BadOne  
Good Luck   More Crap   Wall Bang   Were Up   Were Down    
Insert URL Hyperlink - UBB Code™   Insert Email Address - UBB Code™
Bold - UBB Code™   Italics - UBB Code™
Quote - UBB Code™   Code Tag - UBB Code™
List Start - UBB Code™   List Item - UBB Code™
List End - UBB Code™   Image - UBB Code™

What is UBB Code™?

Disable Graemlins in this post.


T O P I C     R E V I E W
BooDog  - posted
ANTICANCER RESEARCH 32: 4423-4432 (2012)
Adva-27a, a Novel Podophyllotoxin Derivative Found to Be Effective against Multidrug Resistant Human Cancer Cells

In the search for novel etoposide analogs with improved efficacy and pharmacokinetic properties, which can overcome multidrug resistance of human cancer cells, we designed and synthesized Adva-27a, a non-ester, nitrogen-containing glycoside analog of etoposide (Figure 1C). This study describes the evaluation of Adva-27a using a battery of biochemical, cell biological, and pharmacological analyses. Compared to etoposide, Adva-27a was found to be substantially more potent against two multidrug-resistant human cancer cell lines, and has a better metabolic stability and pharmacokinetic properties than etoposide. Taken together, these results suggest that further development of Adva-27a is warranted as a novel topoisomerase II inhibitor for use in human cancer therapy with multidrug-resistant tumors. ript.pdf

Sunshine Biopharma holds the exclusive rights to Adva-27a in the United States. We received this license from Advanomics Corporation which owns the international patent applications filed on April 27, 2007 (PCT/FR2007/000697). These patent applications, which are now issued in Europe and the United States (US 8,236,935) and are still pending elsewhere around the world, were originally owned by Institut National des Sciences Appliquées de Rouen (France) and have recently been purchased by Advanomics Corporation. On January 14, 2013, Advanomics Corporation filed a new patent application covering Adva-27a manufacturing processes as well as new Adva-27a derivatives and other compositions. 2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,236,935.PN.&OS=PN/8,236,935&RS= PN/8,236,935

• Adva-27a is effective at killing different types of multidrug resistant cancer cells, including:
• Breast Cancer (MCF-7/MDR cell line)
• Small Cell Lung Cancer (H69AR cell line)
• Uterine Sarcoma (MES-SA/Dx5 cell line)
• Pancreatic Cancer (Panc-1 cell line)
• Adva-27a is unaffected by P-Glycoprotein, the enzyme responsible for making cancer cells resistant to anti-tumor drugs.
• Adva-27a has excellent clearance time (half-life = 54 minutes) as indicated by human microsomes stability studies and pharmacokinetics data in rats.
• Adva-27a clearance is independent of Cytochrome P450, a mechanism that is less likely to produce toxic intermediates.
• Adva-27a is an excellent inhibitor of Topoisomerase II with an IC50 of only 1.44 micromolar.
• Adva-27a has shown excellent pharmacokinetics profile as indicated by studies done in rats.
• Adva-27a does not inhibit tubulin assembly.

Dr. Steve Slilaty
Dr. Steve N. Slilaty, age 57, was appointed as our CEO, President and Chairman of our Board of Directors on October 15, 2009. In addition, since February 2002, Dr. Slilaty has been President and Chief Scientific Officer of Advanomics Corporation, Montreal, Canada, a privately held company engaged in the research, development and commercialization of drugs for the treatment of various forms of cancer. Advanomics Corporation is the third in a line of biotechnology companies that Dr. Slilaty founded and managed through their early and mid stages of development. The first, Quantum Biotechnologies Inc. later known as Qbiogene Inc., was founded in 1991 and grew to over $60 million in annual sales. Today, Qbiogene is a member of a family of companies owned by MP Biomedicals, one of the largest international suppliers of biotechnology reagents with a catalogue containing over 55,000 products. The second company which Dr. Slilaty founded, Genomics One Corporation, now known as Alert B&C Corporation, conducted an initial public offering (IPO) of its capital stock in 1999 and, on the basis of its ownership of Dr. Slilaty's patented TrueBlue Technology, Genomics One became one of the handful of participants in the Human Genome Project. Formerly a research team leader of the Biotechnology Research Institute, a division of the National Research Council of Canada, Dr. Slilaty also served as a consultant in a management and advisory capacity for a major Canadian biotechnology company between 1995 and 1997 during which time the company completed one of the largest biotechnology IPO‘s in Canada raising over $34 million. Dr. Slilaty received his Ph.D degree from the University of Arizona in 1983 and a Bachelor of Science degree from Cornell University in 1976. In addition, Dr. Slilaty holds a position as Adjunct Professor at Universit-é du Qu-ébec in the Department of Microbiology and Biotechnology.

Sunshine Biopharma Inc.
469 Jean-Talon West
3rd Floor
Montreal, Quebec H3N 1R4
Phone: 514-764-9698
Fax: 514-764-9699
Direct: 514-814-0464
3rd floor office. =69&ll=45.528816,-73.623150&yaw=302.4&thumbpegman=1&w=300&h=118

Garmen Laboratories will manufacture 1 kilogram of Adva-27a, Sunshine Biopharma’s flagship anticancer drug candidate in development for multidrug resistant cancers. The 1-kilogram GMP material will be used to complete the remaining studies required to file an Investigational New Drug application with the U.S. Food and Drug Administration and conduct the Breast Cancer Phase I clinical trial of Adva-27a scheduled to be hosted at McGill University’s Jewish General Hospital in Montreal, Canada.
Garmen Laboratories is a U.S. Food and Drug Administration-registered facility and accredited by Health Canada. More on Garmen Labs can be found at s_Release_Garmen_V2_Final.pdf

McGill University’s Jewish General Hospital

SEC filings... s&filenum=&State=&Country=&SIC=&myowner=exclude&action=getcompany
The number of shares of the registrant’s only class of common stock issued and outstanding as of August 5, 2013, was 56,439,061 shares.
Authorized 200,000,000 Shares; Issued and outstanding 56,439,061 and 51,416,092 at June 30, 2013 and December 31, 2012 respectively.

Trading Information
Stock Price History
Beta: 0.50
52-Week Change3: -12.50%
S&P500 52-Week Change3: 15.69%
52-Week High (Jan 31, 2013)3: 0.46
52-Week Low (Aug 21, 2013)3: 0.17
50-Day Moving Average3: 0.20
200-Day Moving Average3: 0.23

Share Statistics
Avg Vol (3 month)3: 39,959
Avg Vol (10 day)3: 16,414
Shares Outstanding5: 56.44M
Float: 24.22M


SBFM is in the process of changing its incorp from Colorado to Delaware and then to Canada. This move allows them to receive grants directly rather than through their sole parent company Advanomics. They are within a few months of filing their IND which should be a nice catalyst.

As always, do your DD.
BooDog  - posted
Sunshine Biopharma, Inc.

Offer to exchange 56,839,061 Common Shares
for 56,839,061 Common Shares of
Sunshine Biopharma Inc., a Canadian corporation,
that have been registered under the Securities Act of 1933

We have filed a registration statement on Form S-4, of which this Prospectus is a part, to register the issuance of Common Stock that is to be delivered to our shareholders by a to-be-formed Canadian corporation upon the completion of a redomestication of our Company, Sunshine Biopharma, Inc., a Colorado corporation. We are proposing to change our jurisdiction of incorporation from Colorado to Delaware, then to the Canadian federal jurisdiction under the Canada Business Corporations Act (the “CBCA”) through a process known as a continuation under Delaware and Canada corporate law (the “Continuation” or the “Continuance”). In order to give effect to the Continuation, our Board of Directors has adopted a plan of merger under the Colorado Revised Statutes (the “Plan of Merger”) to reincorporate our Company into a Delaware corporation in order to take advantage of the laws of the State of Delaware authorizing a continuation, and simultaneous therewith, to file a Certificate of Transfer with the Delaware Secretary of State to continue our existence as a Canadian corporation.
BooDog  - posted
Still accumulating here. Some volatility for dips in the afternoon. Don't think I'll have enough to require me to file but if this moves on the IND like CTIX did?
Yum. [Cool]
BooDog  - posted
IND likely to take longer than i thought. Maybe by mid to late 2014? 005974-index.htm
Anyone else looking at this I'd recommend some deep DD. Maybe when they're actually close to the IND it may be worth a look.
Lockman  - posted

Has a way to fall, .10 entry.
BooDog  - posted
Originally posted by Lockman:

Has a way to fall, .10 entry.

It's still on my "other" list, .10 or better might be worth a few though.
BooDog  - posted
Target is around .067 now imo.
pennybuilder  - posted

10-Q last week reduced O/S by 28%!!!!!!!!!!!!

pennybuilder  - posted
Big developments to be released. in fact, expect a price jump tomorrow. It will happen.

SBFM is a very hot BioPharma company with FDA and patents. New patents and fda applications were submitted in May for coronavirus.

Watch the charts and trades tomorrow. This stock is going to more than double very quickly.

Contact Us | Message Board Home

© 1997 - 2021 All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2